Table 1.
Baseline characteristics of pregnant women receiving ILPS or NPH insulin.
| ILPSg | NPHg | P | |
|---|---|---|---|
| No. | 53 | 36 | |
| Type of diabetes (T2DM/GDM) | 7/46 | 18/18 | 0.0002 |
| Caucasian ethnicity (%) | 90.6 (48/53) | 91.7 (33/36) | ns |
| Age (yrs) | |||
| Total | 34.7 ± 5.8 | 34.2 ± 4.8 | ns |
| T2DM | 36.0 ± 4.3 | 33.4 ± 5.3 | ns |
| GDM | 34.5 ± 6.0 | 34.9 ± 4.3 | ns |
| Prepregnancy BMI (kg/m2) | |||
| Total | 28.6 ± 5.7 | 28.8 ± 7.2 | ns |
| T2DM | 30.9 ± 6.0 | 29.2 ± 7.2 | ns |
| GDM | 28.3 ± 5.7 | 28.4 ± 7.3 | ns |
| Gestational week at 1st visit | |||
| Total | 22.2 ± 8.4 | 14.1 ± 8.9 | <0.0001 |
| T2DM | 15.4 ± 9.6 | 9.2 ± 6.6 | ns |
| GDM | 23.3 ± 7.8 | 19.0 ± 8.3 | ns |
| Gestational week at enrollment | |||
| Total | 27.8 ± 8.1 | 20.3 ± 11.1 | 0.0004 |
| T2DM | 15.4 ± 13.2 | 11.1 ± 7.1 | ns |
| GDM | 29.1 ± 6.3 | 29.5 ± 4.9 | ns |
| Weight increase at enrollment (kg) | |||
| Total | 7.7 ± 6.7 | 4.4 ± 4.4 | 0.01 |
| T2DM | 4.7 ± 6.7 | 1.7 ± 2.4 | ns |
| GDM | 8.2 ± 6.7 | 7.1 ± 4.3 | ns |
| Preenrollment short-acting insulin dose (units/kg/day) | |||
| Total | 0.18 ± 0.10 | 0.27 ± 0.16 | 0.01 |
| T2DM | 0.22 ± 0.13 | 0.30 ± 0.18 | ns |
| GDM | 0.18 ± 0.09 | 0.23 ± 0.14 | ns |
BMI: body mass index; T2DM: type 2 diabetes mellitus; GDM: gestational diabetes mellitus.